Efficacy and Factors Associated with Treatment Response of Intravenous Immunoglobulin in Inpatients with Refractory Inflammatory Bowel Diseases

Conclusions: Our study demonstrates that IVIG is beneficial in patients with medically refractory IBD, and that concomitant CDI is a risk factor for the treatment failure of IVIG for refractory disease.
Source: Inflammatory Bowel Diseases - Category: Gastroenterology Tags: Future Directions and Methods for IBD Research Source Type: research